The infection may be silent or cause non-specific symptoms
Helicobacter pylori (H. pylori) is a spiral-shaped, flagellated bacterium adapted to colonise the acidic mucus layer of the human stomach lining. By producing the enzyme urease, it converts gastric urea into ammonia and carbon dioxide, neutralising stomach acid in its immediate microenvironment and allowing it to establish lifelong persistence unless actively eradicated [4, 7, 10, 12]. Epidemiological surveys indicate that H. pylori is common worldwide, and prevalence varies substantially across regions and communities [4, 7, 10]. Yet the overwhelming majority of infected people never develop noticeable symptoms or overt clinical illness throughout their lives [4, 12]. Carrying the organism is therefore a microbiological finding rather than an automatic explanation for every sensation of discomfort in the abdomen.
When symptoms do occur, they typically stem from progressive inflammation of the stomach lining (chronic gastritis) or mucosal ulceration in the stomach or duodenum [1, 2, 4, 11]. The most frequent complaint is an ache or burning sensation in the upper abdomen, often between the navel and breastbone, which may worsen when the stomach is empty or wake a person during the night [2, 4, 11, 12]. Other common symptoms include postprandial fullness, early satiety, nausea, excessive belching, bloating, and reduced appetite [2, 4, 12]. Importantly, none of these manifestations is unique to H. pylori. Identical clinical features occur in non-ulcer functional dyspepsia, medication-induced gastric irritation from non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, gallstone disease, or a peptic ulcer that arose without any bacterial involvement [2, 9, 11].
Because upper-gastrointestinal sensations overlap extensively across different conditions, an accurate assessment depends on identifying objective evidence rather than guessing from symptoms alone [8, 10]. International consensus statements, including the Maastricht VI report and the Houston Consensus, stress that treating dyspepsia empirically without verifying active bacterial infection risks unnecessary antibiotic exposure, adverse drug effects, and progressive antimicrobial resistance [7, 8, 10]. A suitable test must establish whether active bacteria are truly present before any clinical decision is made.
Active infection tests versus blood antibody testing
Detecting active H. pylori infection requires diagnostic tools that demonstrate living bacteria rather than historical exposure. The two primary non-invasive options recommended by gastroenterology guidelines are the urea breath test (UBT) and the laboratory stool antigen test (SAT) using monoclonal enzyme immunoassay [5, 7, 8, 10]. In the urea breath test, the patient ingests a solution containing urea labelled with carbon-13 (a safe, non-radioactive isotope); if active bacteria are present in the stomach, bacterial urease rapidly splits the urea, releasing labelled carbon dioxide that is absorbed into the bloodstream and measured in exhaled breath samples [5, 8, 10]. The stool antigen test directly detects specific bacterial structural proteins shed into the stool [5, 8, 12]. Both tests are useful for detecting active infection, although their accuracy depends on the test used and correct preparation [7, 8, 10].
In contrast, blood tests that measure circulating antibodies (serology IgG) against H. pylori are widely misused and frequently cause clinical confusion. While a blood antibody test confirms that the immune system has encountered the bacterium at some point in life, it cannot determine whether an active infection is present right now [6, 7, 8]. Antibodies can remain detectable in the bloodstream for months, years, or even decades following successful antibiotic eradication or spontaneous clearance [7, 8, 10]. For this reason, the 2024 American College of Gastroenterology (ACG) guideline and the Houston Consensus explicitly advise against blood serology for routine diagnostic evaluation or confirming cure [6, 8]. Relying on a positive blood test repeatedly leads to unnecessary antibiotic courses for an infection that was cleared years earlier [6, 8].
Accurate results from the urea breath test and stool antigen test depend strictly on medication preparation. Proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, and pantoprazole can temporarily reduce bacterial load and activity, producing a false-negative result despite ongoing infection [5, 7, 8]. Antibiotics and bismuth subsalicylate formulations directly diminish bacterial numbers in the stomach lining, also causing false negatives [5, 6, 8]. Guidelines therefore mandate that PPIs be held for at least two weeks (fourteen days) before testing, and that all antibiotics and bismuth preparations be discontinued for at least four weeks (twenty-eight days) before undergoing either a breath or stool test [6, 7, 8]. If symptoms are difficult during the washout period, do not stop or substitute treatment independently; ask the clinician or laboratory about a temporary alternative and the timing of the final dose before testing [8, 9].
Endoscopy is not required for everyone: when is direct inspection necessary?
Most patients with straightforward upper-abdominal complaints do not need an invasive procedure as their first diagnostic step. In younger individuals without alarm features, clinical guidelines endorse a non-invasive 'test-and-treat' strategy: identifying active infection via breath or stool testing and treating confirmed cases appropriately [7, 9, 10]. Non-invasive testing avoids unnecessary procedures, especially when symptoms overlap with reflux or irritable bowel syndrome without any red flags. However, diagnostic upper endoscopy (also known as an esophagogastroduodenoscopy or gastroscopy) remains the gold standard when direct visualisation of the mucosal tissue is required [1, 5, 9]. A gastroscopy allows an experienced gastroenterologist to directly examine the lining of the oesophagus, stomach, and duodenum under light sedation, pinpointing mucosal erosion, active bleeding, ulcer craters, or suspicious structural abnormalities [1, 2, 5, 11].
During an endoscopy, the specialist can collect tiny, painless tissue biopsies from specific areas of the gastric antrum and corpus for multiple diagnostic assessments [5, 6, 7]. Biopsy specimens can be examined immediately at the bedside using a rapid urease test (CLO test), or sent to pathology for histopathological evaluation with special stains, which reliably verifies tissue inflammation, glandular atrophy, and intestinal metaplasia [5, 7, 10]. In tertiary centres, biopsies can also be used for bacterial culture or molecular polymerase chain reaction (PCR) testing to identify point mutations responsible for clarithromycin or fluoroquinolone resistance, providing invaluable guidance for treatment planning in challenging or recurrent infections [5, 6, 7].
Direct endoscopic examination becomes urgent when red-flag alarm features are present, regardless of age [2, 4, 9, 11]. These warning signs include vomiting blood or dark brown material resembling coffee grounds, passing black tarry stools (melena), progressive or painful swallowing (dysphagia or odynophagia), unintentional significant weight loss, persistent intractable vomiting, or unexplained iron-deficiency anaemia [2, 4, 6, 9]. The age at which new-onset dyspepsia warrants endoscopy varies by guideline and individual risk, so clinicians consider age alongside the full clinical picture, or who have a first-degree family history of gastric cancer [6, 7, 9]. In these high-risk scenarios, initiating empirical antibiotics without an endoscopy risks delaying the identification of a bleeding ulcer or early neoplasm [6, 9].
H. pylori treatment: a clinician-selected regimen, not an off-the-shelf prescription
H. pylori treatment is not a single antibiotic or an over-the-counter antacid. Eradication requires a combination that includes potent acid suppression with selected antibiotics and, in some regimens, bismuth; using one drug or incomplete doses increases the chance of treatment failure and antimicrobial resistance [3, 5, 6, 7]. If an active-infection test is positive, do not borrow another person's prescription or repeat an old course. The clinician needs to review medicine allergies, previous antibiotic exposure and any earlier H. pylori treatment before selecting a regimen [5, 6, 10].
The combination varies with local resistance, availability of susceptibility testing and the individual's treatment history. The 2024 American College of Gastroenterology guideline prefers optimized bismuth quadruple therapy for 14 days when antibiotic susceptibility is unknown, and advises against empiric clarithromycin- or levofloxacin-containing regimens unless susceptibility is demonstrated [6]. Maastricht VI and World Gastroenterology Organisation guidance apply the same underlying principle: selection should reflect local resistance, prior antibiotic exposure and access to susceptibility testing rather than one universal prescription for every country and patient [7, 10]. Drug names here explain the decision, not a regimen to start without care.
Taking every dose for the prescribed duration matters. If widespread rash, swelling of the face or tongue, breathing difficulty, vomiting that prevents medicine intake or severe diarrhoea develops, seek prompt medical advice rather than changing the regimen independently. Effects such as a metallic taste or temporary darkening of stool can occur with selected medicines, but a clinician or pharmacist should distinguish an expected effect from a reason to stop a drug [5, 6]. A properly timed test of cure is still needed after treatment; symptom improvement alone does not prove eradication [3, 6, 7].
Test of cure and post-treatment recovery: timing and interpretation
Completing a fourteen-day course of medication does not guarantee that H. pylori has been completely eliminated. Even with an appropriate treatment regimen, infection can persist in some patients because of antibiotic resistance or other factors [6, 7, 8]. For this reason, clinical consensus guidelines (including the Houston Consensus and the American College of Gastroenterology recommendations) strongly state that every treated patient should undergo formal confirmation of eradication [6, 7, 8]. Relying on how a person feels is deceptive: a marked reduction in burning or epigastric discomfort often reflects the soothing effect of acid-suppressive therapy or partial mucosal healing, rather than the total clearance of the underlying bacteria [6, 8].
A test of cure must be conducted within a strict diagnostic timeframe to prevent inaccurate readings. The test must be scheduled at least four weeks (twenty-eight days) after completing the entire course of antibiotics and bismuth, and at least two weeks (fourteen days) after stopping proton pump inhibitors [6, 7, 8]. The preferred modalities for post-treatment verification are the laboratory monoclonal stool antigen test or the urea breath test [5, 7, 8]. Blood antibody testing must never be used to evaluate treatment outcome, as IgG antibodies linger for months or years irrespective of successful cure [7, 8, 10]. If a follow-up gastroscopy is already clinically required (for example, to confirm the complete healing of a large gastric ulcer and rule out malignancy) biopsies taken during the procedure for rapid urease testing and histopathology will serve as confirmation [5, 6].
Patients are often puzzled when mild bloating persists after treatment despite taking every dose correctly. It is essential to recognize that ongoing sensations do not necessarily indicate persistent infection. The delicate gastric lining requires weeks or months to fully resolve chronic histological gastritis after the bacteria are gone, and a potent two-week antibiotic regimen can temporarily alter the commensal gut microbiome [7, 10]. Furthermore, functional dyspepsia or irritable bowel symptoms can exist alongside H. pylori [7, 9]. A dedicated medical review evaluates whether persistent complaints stem from slow tissue recovery, post-antibiotic dysbiosis, or an unresolved infection requiring second-line rescue therapy [6, 7].
Distinguishing H. pylori from reflux and irritable bowel syndrome
A frequent source of diagnostic error in clinical practice is confusing H. pylori infection with other common gastrointestinal disorders. In daily conversations, symptoms like 'burning', 'bloating', and 'indigestion' are often attributed reflexively to H. pylori, when they may actually stem from gastro-oesophageal reflux disease (GERD) or irritable bowel syndrome (IBS) [2, 9, 10]. Clinicians distinguish these conditions by evaluating the precise anatomical location and physiological triggers of the symptoms [2, 9]. Gastro-oesophageal reflux typically causes retrosternal acid reflux, a rising burning sensation behind the breastbone toward the throat, often accompanied by acid regurgitation and aggravated by bending forward or lying supine after a large meal [2, 9, 11]. In contrast, H. pylori-associated pain is concentrated in the epigastric region (upper abdomen) and is frequently related to gastric emptying and mucosal acid contact [2, 4, 11].
Similarly, lower-abdominal complaints must not be mistaken for stomach bacterial disease. Irritable bowel syndrome is a disorder of gut-brain interaction characterized by recurrent lower abdominal cramping or pain linked to bowel movements, along with distinct shifts in stool frequency or appearance, such as constipation, diarrhoea, or alternating patterns [9, 10]. While H. pylori can cause upper abdominal fullness and belching, it does not directly drive lower bowel disturbances or chronic colonic hypersensitivity [7, 9]. Patients struggling with irritable bowel syndrome symptoms do not benefit from repeated H. pylori antibiotic treatments unless active bacterial gastritis is objectively demonstrated [7, 9]. A careful medical history prevents misattributing colon or oesophageal complaints to the stomach, ensuring that each patient receives targeted, effective management [9, 10].
When to seek medical assessment: specialist care at La Rose Clinics
Arranging a consultation with an internal medicine or gastroenterology specialist is indicated whenever upper-abdominal burning, gnawing pain, or post-meal discomfort persists for more than two to three weeks, recurs regularly, or interferes with restful sleep and normal nutrition [2, 4, 8]. Professional guidance is equally essential if you have received an ambiguous laboratory result (such as an unexplained positive blood antibody report) or if symptoms continue following a previous, unverified antibiotic course [6, 8]. Before your visit, gather all earlier laboratory printouts, endoscopy reports, and a complete, dated list of medications and dietary supplements. If the person experiencing abdominal pain is a young child, remember that assessing H. pylori in children follows distinct pediatric gastroenterology protocols and requires tailored decision-making.
Certain severe warning symptoms require immediate or urgent medical evaluation rather than an outpatient appointment [2, 4, 11]. Seek emergency assessment at once if you experience vomiting blood or dark brown material, passing black tarry stools, a sudden onset of severe, unrelenting abdominal pain, episodes of dizziness or fainting, persistent inability to keep liquids down, or rapid unintentional weight loss [2, 4, 6, 11]. These critical red flags point toward serious acute complications, including peptic ulcer perforation or active gastrointestinal haemorrhage, which require prompt intervention in a hospital setting [2, 11].
At La Rose Clinics, assessment begins with the symptom pattern, medicines and previous test results, after which the treating clinician decides whether active-infection testing, gastroscopy or another diagnostic route is appropriate. The aim is a clear plan without indiscriminate antibiotics or guaranteed outcomes. When you need an organized review and a suitable next step, you can request an appointment with the medical team [6, 8, 9].
